Showing Results for
- Academic Journals (37)
Search Results
- 37
Academic Journals
- 37
- Search Terms:
- 1From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedAuthor(s): Henry I. Miller [1] A persistent criticism of the Bush administration, according to polls, is that its policies too often favor the interests of big business over those of consumers. Although these...
- 2From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedAuthor(s): Liz Fletcher [1] At the end of July, International Business Machines (IBM; Armonk, NY) chalked up a $27 million deal with the Korean Institute of Science and Technology to build and maintain what will become...
- 3From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedAuthor(s): Sylvia Davidson [1] In an effort to increase the competitiveness of the European drug development industry, the European Commission announced proposals in mid-July aimed at streamlining and speeding up the...
- 4From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedGetting a fix on nitrogen Nitrogen fixation is essential to life, as without it there would be no proteins or DNA. Now, Sharon Long, professor of biological sciences at Stanford University (Stanford, CA), and an...
- 5From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedLast month marked a low point for stem cell research in particular, and biotechnology in general. First, the US House of Representatives voted overwhelmingly in favor of a flawed act banning any form of human cloning...
- 6From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedAuthor(s): Ronald I. Eisenstein [1]; David S. Resnick [1] Blockbuster patents enrich university coffers, but can also affect future patenting and research decisions. Universities and nonprofit research institutes...
- 7From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedAuthor(s): Terry Gaasterland [1]; Kass Schmitt [1] The Shattered Self: The End of Natural Evolution By Pierre Baldi MIT Press; $24.95, 245 pp, , 2001 The nearly possible, sometimes coined "fiction science", is...
- 8From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedAuthor(s): H. Michael Keyoung [1, 7]; Neeta S. Roy [1, 7]; Abdellatif Benraiss [1]; Abner Louissaint, Jr. [1]; Akira Suzuki [3, 4]; Mitsuhiro Hashimoto [5]; William K. Rashbaum [2]; Hideyuki Okano [3, 4, 6]; Steven A....
- 9From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedAuthor(s): Carolyn Raffensperger [1]; Katherine Barrett [2] To the editor As representatives of one of the civil society organizations mentioned in Miller and Conko's Commentary on the precautionary principle (...
- 10From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedAuthor(s): Liz Fletcher [1] At the end of July, Brazil's government was flirting with the authorization for the release of Monsanto's Roundup Ready soy for planting, potentially reversing an earlier moratorium on the...
- 11From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedAuthor(s): Stefan Krebs (corresponding author) [1]; Doris Seichter [2]; Martin Förster [1, 2] We extended the primer sequences for the amplification of STR loci at the 5' and 3' ends in order to incorporate a sequence...
- 12From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedAuthor(s): Emma Dorey [1] On July 25, the European Commission (EC; Brussels, Belgium) adopted a system for labeling and tracing food and feed derived from genetically modified organisms (GMOs). While the aim is to...
- 13From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedAuthor(s): Paul Smaglik [1] Ian Smith was intrigued enough by the intellectual allures of the stock market that he abandoned basic science. Michael Steinmetz noticed that his pharmaceutical employer was spending less...
- 14From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedAuthor(s): Jeffrey L. Fox [1] In a speech televised in August from his Texas home, US President George W. Bush endorsed a plan for funding human embryonic stem (ES) cell research in the public sector, while imposing...
- 15From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedAuthor(s): Matthew A. Cooper (corresponding author) [1]; Fedor N. Dultsev [1]; Tony Minson [2]; Victor P. Ostanin [1]; Chris Abell [1]; David Klenerman (corresponding author) [1] Rupture event scanning (REVS) can be...
- 16From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedAuthor(s): André Bernard (corresponding author) [1, 3]; Dora Fitzli [2]; Peter Sonderegger [2]; Emmanuel Delamarche [1]; Bruno Michel [1]; Hans Rudolf Bosshard [2]; Hans Biebuyck [1, 4] The placement of functional...
- 17From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedAuthor(s): Emma Dorey [1] Despite 6 years of international negotiation, the United States has rejected a Protocol to strengthen the Biological Weapons Convention (BWC). The draft Protocol "will not enhance our...
- 18From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedBritish Biotech (Oxford, UK) has announced the resignation of Giles Campion as director of research and development and chief medical officer at the end of September 2001. No replacement has been named, and R&D functions...
- 19From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedAuthor(s): Hideki Taguchi [1, 3]; Taro Ueno [2, 3]; Hisashi Tadakuma [2, 3]; Masasuke Yoshida (corresponding author) [1]; Takashi Funatsu [2] Existing approaches for studying protein-protein interactions include the...
- 20From: Nature Biotechnology. (Vol. 19, Issue 9) Peer-ReviewedAuthor(s): Cheryl Norrie [1] The New Zealand government faces a challenge living up to its rhetoric of supporting the development of a knowledge economy, while appearing responsive to widespread public aversion to...